GammaTile is a Food and Drug Administration (FDA)-licensed device consisting of four
cesium-131 (Cs-131) radiation-emitting seeds in the collagen tile about the postage stamp …

Glioblastoma multiforme (GBM) is the most common malignant brain tumor that affects
approximately 17,000 patients annually. Clear survival advantages have been …

Purpose Valproic acid (VPA) is an antiepileptic agent with histone deacetylase inhibitor
(HDACi) activity shown to sensitize glioblastoma (GBM) cells to radiation in preclinical …

Glioblastoma multiforme (GBM) is a primary brain tumor that is very aggressive, resistant to
treatment, and characterized by a high degree of anaplasia and proliferation. Routine …

Glioblastoma is the most common primary malignant neoplasm of the central nervous
system in adults. Standard of care is resection followed by chemo-radiation therapy. Despite …

Abstract Background GammaTile®(GT) is a recent US Food and Drug Administration (FDA)
cleared brachytherapy platform. Here, we report clinical outcomes for recurrent glioblastoma …

Background 211 At is a high-energy α-ray emitter with a relatively short half-life and a high
cytotoxicity for cancer cells. Its dispersion can be imaged using clinical scanners, and it can …

There is growing evidence that antitumor treatment contributes to better seizure control in
low-grade glioma patients. We performed a systematic review of the current literature on …

Brachytherapy (BT) for glioblastoma multiforme (GBM) involves the use of radioactive
isotopes to deliver ionizing radiation directly into the tumor bed. Its application as a means to …

Target population These recommendations apply to adult patients diagnosed with newly
diagnosed glioblastoma. Question 1 In adult patients (aged 65 and under) with newly …